Procter & Gamble: The Market Is Wrong - It's Time To Buy This Compounder (Rating Upgrade)
Summarize this article with:
PropNotes9.81K FollowersFollow5ShareSavePlay(12min)CommentsSummaryProcter & Gamble (PG) offers a compelling buy opportunity as a high-quality, low-beta compounder at a multi-year valuation low.PG has delivered consistent top- and bottom-line growth, with TTM revenue rising from $73B to $84B and TTM profits growing from $13.9B to $16.7B over the last five years.Management has reduced share count by 7% since 2021 through disciplined buybacks, supporting EPS growth and long-term shareholder value.Despite near-term headwinds from inflation and trade tensions, PG's scale, inelastic demand, and portfolio optimization underpin its long-term appeal. aquaArts studio/iStock via Getty Images Previously, I rated PG a 'Hold' in an article where I argued that selling puts on the stock was the most attractive way to generate returns. Now, more than a year on, and with the stockThis article was written byPropNotes9.81K FollowersFollowHere at PropNotes, I focus on uncovering high-yield investment opportunities for individual investors.With a background in professional prop trading, my goal is to break down complex concepts into clear, actionable insights that help you achieve better returns.Follow me today and take control of your portfolio.Analyst’s Disclosure:I/we have a beneficial long position in the shares of PG either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.